Clinical Outcomes of Patients with Recurrent Microsatellite-Stable Endometrial Cancer in Early-Phase Immunotherapy Clinical Trials

• Published in: Cancers Vol. 14; no. 15; p. 3695
• Main Authors: How, Jeffrey A., Jazaeri, Amir A., Fu, Siqing, Rodon Ahnert, Jordi, Gong, Jing, Stephen, Bettzy, Ferreira Dalla Pria, Hanna, Bhosale, Priya, Johnson, Amber, Yuan, Ying, Meric-Bernstam, Funda, Naing, Aung
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 29.07.2022; MDPI
• Subjects: Cancer; Cancer therapies; Clinical outcomes; Clinical trials; Disease control; Endometrial cancer; Endometrium; FDA approval; Histology; Immune checkpoint inhibitors; Immunotherapy; Microsatellite instability; Monoclonal antibodies; Mutation; Oncology; Patients; Review boards; Survival; Tumors
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers14153695

Recurrent microsatellite stable (MSS) endometrial cancer has poor response to conventional therapy and limited efficacy with immune checkpoint monotherapy. We conducted a retrospective study of recurrent MSS endometrial cancer patients enrolled in immunotherapy-based clinical trials at MD Anderson Cancer Center between 1 January 2010 and 31 December 2019. Patients were evaluated for radiologic response using RECIST 1.1 criteria, progression-free survival (PFS), and overall survival (OS). Thirty-five patients were treated with immune checkpoint inhibitors: 8 with monotherapy, 17 with immunotherapy (IO) in combination with another IO-only, and 10 with IO in combination with non-IO therapy. Among those treated with combination IO plus non-IO therapy, one had a partial response but 50% had clinical benefit. Patients who received combination IO plus non-IO therapy had improved PFS compared to those who received monotherapy (HR 0.56, 95% CI 0.33–0.97; p = 0.037) or combination IO-only therapy (HR 0.36, 95% CI 0.15–0.90; p = 0.028) and had improved OS when compared to monotherapy after adjusting for prior lines of therapy (HR 0.50, 95% CI 0.27–0.95; p = 0.036). The potential beneficial clinical outcomes of combination IO plus non-IO therapy in MSS endometrial cancer should be validated in a larger study.